Vertex Pharmaceuticals Inc banner

Vertex Pharmaceuticals Inc
XETRA:VX1

Watchlist Manager
Vertex Pharmaceuticals Inc Logo
Vertex Pharmaceuticals Inc
XETRA:VX1
Watchlist
Price: 227.65 EUR 1.16% Market Closed
Market Cap: €89.4B

Wall St Price Targets

VX1 Price Targets Summary
Vertex Pharmaceuticals Inc

Wall Street analysts forecast VX1 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VX1 is 491.06 EUR with a low forecast of 307.08 EUR and a high forecast of 594.7 EUR.

Lowest Forecast
Price Target
307.08 EUR
35% Upside
Average Forecast
Price Target
491.06 EUR
116% Upside
Highest Forecast
Price Target
594.7 EUR
161% Upside
Vertex Pharmaceuticals Inc Competitors:
Price Targets
VAC
Pierre et Vacances SA
14% Upside
PGEN
Precigen Inc
90% Upside
AYTU
Aytu Biopharma Inc
329% Upside

Revenue
Forecast

17% / Year
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
17% / Year
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 8 years is 10%.

Gross Profit
Forecast

17% / Year
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
17% / Year
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 17%. The projected CAGR for the next 8 years is 10%.

Operating Income
Forecast

42% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-21%
Average Miss
42% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-21%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 42%. The projected CAGR for the next 8 years is 15%.

Pre-Tax Income
Forecast

47% / Year
Past Growth
21% / Year
Estimated Growth
Estimates Accuracy
-14%
Average Miss
47% / Year
Past Growth
21% / Year
Estimated Growth
Estimates Accuracy
-14%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 47%. The projected CAGR for the next 3 years is 21%.

Net Income
Forecast

N/A
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss
N/A
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss

The compound annual growth rate for Net Income over the next 8 years is 14%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is VX1's stock price target?
Price Target
491.06 EUR

According to Wall Street analysts, the average 1-year price target for VX1 is 491.06 EUR with a low forecast of 307.08 EUR and a high forecast of 594.7 EUR.

What is the Revenue forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
10%

Over the last 13 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 8 years is 10%.

What is the Gross Profit forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
10%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 17%. The projected CAGR for the next 8 years is 10%.

What is the Operating Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
15%

Over the last 13 years, the compound annual growth rate for Operating Income has been 42%. The projected CAGR for the next 8 years is 15%.

What is the Pre-Tax Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
21%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 47%. The projected CAGR for the next 3 years is 21%.

What is the Net Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
14%

The compound annual growth rate for Net Income over the next 8 years is 14%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett